Skip to content

See only:

Clinical Evidence

Clinical Evidence | Highlights

Tablo® is clinically effective, reliable and preferred by patients and clinicians

300 mL/min Qd achieves adequacy at 3x/week

Patients across a large weight range achieved adequacy targets at similar frequencies with similar treatment times doing thrice weekly hemodialysis on Tablo as compared with traditional 500 mL/min dialysate flow rates.

Patients are more likely to try home hemodialysis with Tablo

An online survey of 202 U.S. patients with kidney failure currently treating with home hemodialysis (HHD), peritoneal dialysis (PD) or in-center dialysis (ICD) was conducted using a blinded HHD system concept that reflects the benefits and features of the Tablo system.

77% of participants on either ICD or PD responded that Tablo’s features would make them more likely to try HHD.

Patients feel better, sleep better on Tablo

As measured by the Dialysis Symptom Index (DSI), patients with ESKD on standard thrice weekly in-center dialysis reported fewer, less severe dialysis-related symptoms when converted to Tablo. Treatment time, frequency, adequacy and lab results were similar on Tablo and non-Tablo devices. Additionally, patients in the IDE trial using the Tablo system 4 days/week reported having an easier time falling asleep, staying asleep and feeling rested compared to their baseline.

Qd of 300 mL/min achieves similar clearance as ≥500 mL/min

A retrospective observational study of critically ill patients requiring bedside dialysis sought to compare urea clearance between mid and conventional dialysate flow rates, and the effect of filter size in real life clinical setting.

The study found that small solute clearance, represented by URR, delivered in critically ill patients was higher in dialysis treatments with Qd of 300 vs. 600 mL/min. However, this difference was offset by the use of a larger dialyzer. These findings may have implications in hospital settings where water preservation is of priority.

Patients can be trained on Tablo in under 2 weeks

Conversion of an HHD program to Tablo can allow shortened training time, the ability to decrease treatment frequency while achieving adequate clearance and result in favorable patient and nurse experience.

Standard facility training time prior to Tablo was 4-6 weeks. For all patients in this study, Tablo training was completed in two weeks with an average training time of 38 hours.

Nurses can be trained on Tablo in less than 4 hours

After standard Tablo training (under 4 hours), nurses of varied experience and areas of specialty reported high levels of satisfaction with their training, found Tablo easy to learn and use and were confident in treating patients independently.

The survey results affirmed general observation that the Tablo Hemodialysis System can allow training of a wide range of staff to efficiently expand a facility’s renal replacement capabilities.

Tablo continues to demonstrate its clinical versatility, from the hospital to the home.

Latest publications

1873-v6

DISCLAIMERS:

The Tablo® Hemodialysis System and TabloCart™ is indicated for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute or chronic care facility. Treatments must be administered under physician’s prescription and observed by a trained individual who is considered competent in the use of the device. The Tablo Hemodialysis System is also indicated for use in the home. Treatment types available include Intermittent Hemodialysis (IHD), Sustained Low Efficiency Dialysis (SLED/ SLEDD), Prolonged Intermittent Renal Replacement Therapy (PIRRT), and Isolated Ultrafiltration.

This device is not indicated for continuous renal replacement therapy (CRRT) and is cleared for use for up to 24 hours. The dialysate generated by this device is not sterile and should not be used for intravenous (IV) infusion.
2214-v1
Stay connected
© 2024 Outset Medical, Inc. All rights reserved. Outset, Tablo, TabloCart, MyTablo, TabloHub, and Better Begins Now are trademarks of our company.